 Connection
David Moreno to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications David Moreno has written about Antiretroviral Therapy, Highly Active.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.046 |
|
|
|
-
Palladino C, Briz V, Policarpo SN, Silveira LF, de José MI, González-Tomé MI, Moreno D, León Leal JA, Mellado MJ, de Ory SJ, Ramos JT, Muñoz-Fernández MA. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2010 Jun; 29(6):563-6.
Score: 0.018
-
Micheloud D, Jensen J, Bellón JM, Gurbindo D, de José MI, Moreno D, Ramos JT, Muñoz-Fernández MA, Resino S. Slow progression of human immunodeficiency virus and hepatitis C virus disease in a cohort of coinfected children. Pediatr Infect Dis J. 2007 Sep; 26(9):846-9.
Score: 0.015
-
Ramos JT, de José MI, Polo R, Fortuny C, Mellado MJ, Muñoz-Fernández MA, Beceiro J, Bertrán JM, Calvo C, Chamorro L, Ciria L, Guillén S, González-Montero R, González-Tomé MI, Gurbindo MD, Martín-Fontelos P, Martínez-Pérez J, Moreno D, Muñoz-Almagro MC, Mur A, Navarro ML, Otero C, Rojo P, Rubio B, Saavedra J. [Recommendations of the CEVIHP/SEIP/AEP/PNS on antiretroviral treatment in HIV-infected children and teenagers]. Enferm Infecc Microbiol Clin. 2005 May; 23(5):279-312.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|